Nordic Life Science 1
TOP STORIES BUSINESS ACQU I SITIONS // AGREEMENTS
// COLLABORATIONS WE S T SWEDEN Construction of GoCo Active Lab has begun The start of the construction of the new facility was celebrated with a major event on January 25th. R&D ULTIMOVACS RECEIVES EMA ORPHAN DRUG DESIGNATION The European Medicines Agency has issued a positive opinion on the company’s application for Orphan Drug Designation (ODD) for its therapeutic cancer vaccine UV1 for the treatment of mesothelioma. THE DESIGNATION was granted based on results from the Phase II clinical trial, NIPU evaluating UV1 added to ipilimumab and nivolumab treatment in patients with malignant pleural mesothelioma. “The EMA’s Orphan Drug Designation for UV1 in mesothelioma is an important step forB U S IN E S S FluoGuide updates its corporate strategy THE COMPANY PLANS to expand the scope of application of FG001 and advance its development toward approval in aggressive brain cancer. FluoGuide has obtained clinical proof of concept of FG001, a fluorescent molecule targeting the cancer specific uPAR receptor, which lights up cancer cells to improve outcomes of surgery. This includes positive phase II data across three indications: aggressive brain cancer (high grade glioma), head & neck cancer, and lung cancer. FG001 has been granted U.S. Orphan Drug designation in aggressive brain cancer (high grade glioma). Based on this foundation, the company has now announced that it plans to expand the scope of application of FG001 and advance its development toward approval in aggressive brain cancer. NLS ward in the development of our cancer vaccine in this indication,” says Carlos de Sousa, CEO of Ultimovacs. “It allows for important regulatory and commercial benefits and provides us with the potential to rapidly advance UV1 for a patient population with poor prognosis and a high unmet medical need." NLS IN MAY 2023, Sweden’s innovation agency Vinnova decided to invest SEK 160 million in the innovation platform at GoCo Health Innovation City, located in Mölndal outside Gothenburg. Construction is now starting on GoCo Active Lab, where research into new drugs and therapies will be combined with a unique approach to accelerate development in preventive healthcare. Parallel to the development of GoCo Active Lab, the district is growing rapidly with more operations. Already today, over 70 actors have moved in. Collaboration across borders is the core of the entire GoCo Health Innovation City, and the current GoCo Active Lab is a clear example of the triple helix model as a lever for innovation in Swedish life science, state the initiators. NLS GoCo Active Lab 14 | NORDICLIFESCIENCE.ORG PHOTO ANTON SOGGIU